InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
2
已披露卖出
0
T+90 胜率
100%
T+90 平均收益
+48.3%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the full record of transactions filed by Danahy Kevin Patrick, Directeur Commercial. Insider active across 1 company, notably Pulse Biosciences, INC.. Cumulatively, 8 filings have been logged. Breakdown: 2 buys · 0 sell. Total volume traded: €44k. Activity tracked since 30 September 2022. The latest transaction was filed on 18 February 2026 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Danahy Kevin Patrick
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
5,000 股@ US$1.534.8% 占其流量Common StockSEC:0001437749-26-005144:0
20,000 股@ US$1.530.0015% mcap22.3% 占其流量Common StockSEC:0001437749-26-004438:0
20,000 股@ US$1.530.0015% mcap22.4% 占其流量Common StockSEC:0001437749-26-003840:0
4,600 股@ US$1.530.0004% mcap5.2% 占其流量Common StockSEC:0001437749-25-030665:0
20,000 股@ US$1.5320.4% 占其流量Common StockSEC:0001437749-25-029646:0
650 股Common StockSEC:0001437749-24-022356:0
4,781 股@ US$6.519918.0% 占其流量Common StockSEC:0001437749-23-032410:0
标准退出：2024年2月14日 (T+90)
6,500 股@ US$2.309.6% 占其流量Common StockSEC:0001839882-22-022698:0
标准退出：2022年12月29日 (T+90)
8 条申报中的 8 条
About Danahy Kevin Patrick
Danahy Kevin Patrick is the Chief Commercial Officer of PULSE BIOSCIENCES, INC. He oversees the business strategy and development of the company, which focuses on medical technologies. His role is essential in positioning PULSE as a leader in the health solutions sector.
